Glomustumoren en herediteit

Contains fulltext : mmubn000001_026643332.pdf (publisher's version ) (Open Access)Promotores : P. van den Broek en S. Geerts116 p

New hydraulic insights into rapid sand filter bed backwashing using the Carman–Kozeny model

Fluid flow through a bed of solid particles is an important process that occurs in full-scale water treatment operations. The Carman–Kozeny model remains highly popular for estimating the resistance across the bed. It is common practice to use particle shape factors in fixed bed state to match the predicted drag coefficient with experimentally obtained drag coefficients. In fluidised state, however, where the same particles are considered, this particle shape factor is usually simply omitted from the model without providing appropriate reasoning. In this research, it is shown that a shape factor is not a constant particle property but is dependent on the fluid properties as well. This dynamic shape factor for irregularly shaped grains increases from approximately 0.6 to 1.0 in fluidised state.We found that unstable packed beds in moderate up-flow conditions are pseudo-fixed and in a setting state. This results in a decreasing bed voidage and simultaneously in a decreasing drag coefficient, which seems quite contradictory. This can be explained by the collapse of local channels in the bed, leading to a more uniform flow distribution through the bed and improving the available surface for flow-through. Our experimental measurements show that the drag coefficient decreases considerably in the laminar and transition regions. This is most likely caused by particle orientation, realignment and rearrangement in particles’ packing position.A thorough hydraulic analysis shows that up-flow filtration in rapid sand filters under backwash conditions causes the particle bed to collapse almost imperceptibly. In addition, an improved expression of the drag coefficient demonstrated that the Carman–Kozeny model constant, however often assumed to be constant, is in fact not constant for increasing flow rates. Furthermore, we propose a new pseudo-3D image analysis for particles with an irregular shape. In this way, we can explain the successful method using optimisation of the extended terminal sub-fluidisation wash (ETSW) filter backwashing procedure, in which turbidity and peaks in the number of particles are reduced with a positive effect on water quality.Complex Fluid ProcessingSanitary Engineerin

Survival of patients with cancer with DPYD variant alleles and dose-individualized fluoropyrimidine therapy: a matched-pair analysis

PURPOSEDPYD-guided fluoropyrimidine dosing improves patient safety in carriers of DPYD variant alleles. However, the impact on treatment outcome in these patients is largely unknown. Therefore, progression-free survival (PFS) and overall survival (OS) were compared between DPYD variant carriers treated with a reduced dose and DPYD wild-type controls receiving a full fluoropyrimidine dose in a retrospective matched-pair survival analysis.METHODSData from a prospective multicenter study (ClinicalTrials.gov identifier: NCT02324452) in which DPYD variant carriers received a 25% (c.1236G>A and c.2846A>T) or 50% (DPYD*2A and c.1679T>G) reduced dose and data from DPYD variant carriers treated with a similarly reduced dose of fluoropyrimidines identified during routine clinical care were obtained. Each DPYD variant carrier was matched to three DPYD wild-type controls treated with a standard dose. Survival analyses were performed using Kaplan-Meier estimates and Cox regression.RESULTSIn total, 156 DPYD variant carriers and 775 DPYD wild-type controls were available for analysis. Sixty-one c.1236G>A, 25 DPYD*2A, 13 c.2846A>T, and-when pooled-93 DPYD variant carriers could each be matched to three unique DPYD wild-type controls. For pooled DPYD variant carriers, PFS (hazard ratio [HR], 1.23; 95% CI, 1.00 to 1.51; P = .053) and OS (HR, 0.95; 95% CI, 0.75 to 1.51; P = .698) were not negatively affected by DPYD-guided dose individualization. In the subgroup analyses, a shorter PFS (HR, 1.43; 95% CI, 1.10 to 1.86; P = .007) was found in c.1236G>A variant carriers, whereas no differences were found for DPYD*2A and c.2846A>T carriers.CONCLUSIONIn this exploratory analysis, DPYD-guided fluoropyrimidine dosing does not negatively affect PFS and OS in pooled DPYD variant carriers. Close monitoring with early dose modifications based on toxicity is recommended, especially for c.1236G>A carriers receiving a reduced starting dose.Personalised Therapeutic

DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis

Experimentele farmacotherapi

A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy

Experimentele farmacotherapi

A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy

Experimentele farmacotherapi

DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis

Experimentele farmacotherapi